Abstract:The first antibiotics with low nanomolar activity against the multidrug‐resistant Mycobacterium abscessus are achieved by rational redesign of rifamycins. Structure‐based modification on rifamycin ansa‐chain, together with microbiological, biochemical, biophysical and in vivo characterizations, provides novel candidates that are 300‐fold more active than rifampicin, completely bypass the resistance, and possess promising pharmacokinetic profiles. Rifamycin antibiotics are a valuable class of antimicrobials for treating infections by mycobacteria and other persistent bacteria owing to their potent bactericidal activity against replicating and non‐replicating pathogens. However, the clinical utility of rifamycins against Mycobacterium abscessus is seriously compromised by a novel resistance mechanism, namely, rifamycin inactivation by ADP‐ribosylation. Using a structure‐based approach, we rationally redesign rifamycins through strategic modification of the ansa‐chain to block ADP‐ribosylation while preserving on‐target activity. Validated by a combination of biochemical, structural, and microbiological studies, the most potent analogs overcome ADP‐ribosylation, restored their intrinsic low nanomolar activity and demonstrated significant in vivo antibacterial efficacy. Further optimization by tuning drug disposition properties afforded a preclinical candidate with remarkable potency and an outstanding pharmacokinetic profile.

Rational design of a new antibiotic class for drug-resistant infections

A Macromolecule Reversing Antibiotic Resistance Phenotype and Repurposing Drugs as Potent Antibiotics

Computer-aided drug design to generate a unique antibiotic family

A synthetic antibiotic class with a deeply-optimized design for overcoming bacterial resistance

A new class of antibiotics acts as molecular glue

Discovery and optimization of tetrahydroacridine derivatives as a novel class of antibiotics against multidrug-resistant Gram-positive pathogens by targeting type I signal peptidase and disrupting bacterial membrane

Designer broad-spectrum polyimidazolium antibiotics

A new class of synthetic retinoid antibiotics effective against bacterial persisters

Fighting Antimicrobial Resistance: Innovative Drugs in Antibacterial Research

Redesign of Rifamycin Antibiotics to Overcome ADP‐Ribosylation‐Mediated Resistance

Discovery and chemical optimisation of a Potent, Bi-cyclic (Bicycle ) Antimicrobial Inhibitor of PBP3

Discovery and Optimization of nTZDpa as an Antibiotic Effective Against Bacterial Persisters

A novel antibiotic class targeting the lipopolysaccharide transporter

A Novel Chemical Biology and Computational Approach to Expedite the Discovery of New-Generation Polymyxins Against Life-Threatening Acinetobacter Baumannii

Repurposing of nucleoside- and nucleobase-derivative drugs as antibiotics and biofilm inhibitors

Pyridylpiperazine-based allosteric inhibitors of RND-type multidrug efflux pumps

Towards the sustainable discovery and development of new antibiotics

Rational Design of Dimeric Lysine N-Alkylamides as Potent and Broad-Spectrum Antibacterial Agents.

A new antibiotic selectively kills Gram-negative pathogens

Antibacterial Drug Leads Targeting Isoprenoid Biosynthesis

Development of a Fragment-Based Machine Learning Algorithm for Designing Hybrid Drugs Optimized for Permeating Gram-Negative Bacteria